Journal of Clinical Oncology, Vol 10, 257-263, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

C Jacobs, G Lyman, E Velez-Garcia, KS Sridhar, W Knight, H Hochster, LT Goodnough, JE Mortimer, LH Einhorn and L Schacter
Stanford University School of Medicine, CA.

PURPOSE: To determine whether combination chemotherapy is superior to single agents for recurrent/metastatic head and neck cancer, we compared the efficacy and toxicity of cisplatin (CP) and fluorouracil (5-FU), alone and in combination in a phase III trial. PATIENTS AND METHODS: Two hundred forty-nine patients with recurrent head and neck cancer were randomized to one of three treatments: CP (100 mg/m2) and 5- FU (1 g/m2 x 4), CP, or 5-FU every 3 weeks. RESULTS: The overall response rate to the combination (32%) was superior to that of CP (17%) or 5-FU (13%) (P = .035). Response was associated with good performance status (PS) but not with primary site, site of recurrence, histology, prior irradiation, or relative dose intensity. Median time to progression was less than 2.5 months, and there was no significant difference in median survival (5.7 months) among the groups. By multivariate analysis, patients with better PS and poorly differentiated tumors had superior survival. Hematologic toxicity and alopecia were worse in the combination arm. CONCLUSION: Although the response rate to the combination of CP plus 5-FU was superior to that achieved with single agents, survival did not improve.

This article has been cited by other articles:

				R. I. Haddad, L. J. Weinstein, T. J. Wieczorek, N. Bhattacharya, H. Raftopoulos, M. W. Oster, X. Zhang, V. M. Latham Jr., R. Costello, J. Faucher, et al. A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck: Modulation of Retinoblastoma Protein Phosphorylation by a Novel Chloroindolyl Sulfonamide Cell Cycle Inhibitor Clin. Cancer Res., July 15, 2004; 10(14): 4680 - 4687. [Abstract] [Full Text] [PDF]

				M. E. Dolan, K. G. Newbold, R. Nagasubramanian, X. Wu, M. J. Ratain, E. H. Cook Jr., and J. A. Badner Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity Cancer Res., June 15, 2004; 64(12): 4353 - 4356. [Abstract] [Full Text] [PDF]

				E. E.W. Cohen, M. W. Lingen, and E. E. Vokes The Expanding Role of Systemic Therapy in Head and Neck Cancer J. Clin. Oncol., May 1, 2004; 22(9): 1743 - 1752. [Abstract] [Full Text] [PDF]

				A. Argiris, Y. Li, B. A. Murphy, C. J. Langer, and A. A. Forastiere Outcome of Elderly Patients With Recurrent or Metastatic Head and Neck Cancer Treated With Cisplatin-Based Chemotherapy J. Clin. Oncol., January 15, 2004; 22(2): 262 - 268. [Abstract] [Full Text] [PDF]

				K. J. Cullen, K. A. Newkirk, L. M. Schumaker, N. Aldosari, J. D. Rone, and B. R. Haddad Glutathione S-Transferase {pi} Amplification is Associated with Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines and Primary Tumors Cancer Res., December 1, 2003; 63(23): 8097 - 8102. [Abstract] [Full Text] [PDF]

				M. L. Fishel, S. M. Delaney, L. D. Friesen, R. J. Hansen, E. G. Zuhowski, R. C. Moschel, M. J. Egorin, and M. E. Dolan Enhancement of Platinum-induced Cytotoxicity by O6-Benzylguanine Mol. Cancer Ther., July 1, 2003; 2(7): 633 - 640. [Abstract] [Full Text] [PDF]

				E. E. W. Cohen, F. Rosen, W. M. Stadler, W. Recant, K. Stenson, D. Huo, and E. E. Vokes Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., May 15, 2003; 21(10): 1980 - 1987. [Abstract] [Full Text] [PDF]

				B. L. Wenig, J. A. Werner, D. J. Castro, K. S. Sridhar, H. S. Garewal, W. Kehrl, A. Pluzanska, O. Arndt, P. D. Costantino, G. M. Mills, et al. The Role of Intratumoral Therapy With Cisplatin/Epinephrine Injectable Gel in the Management of Advanced Squamous Cell Carcinoma of the Head and Neck Arch Otolaryngol Head Neck Surg, August 1, 2002; 128(8): 880 - 885. [Abstract] [Full Text] [PDF]

				C. Monnerat, S. Faivre, S. Temam, J. Bourhis, and E. Raymond End points for new agents in induction chemotherapy for locally advanced head and neck cancers Ann. Onc., July 1, 2002; 13(7): 995 - 1006. [Abstract] [Full Text] [PDF]

				B. S. Glisson, B. A. Murphy, G. Frenette, F. R. Khuri, and A. A. Forastiere Phase II Trial of Docetaxel and Cisplatin Combination Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., March 15, 2002; 20(6): 1593 - 1599. [Abstract] [Full Text] [PDF]

				D. J. Adelstein, J. P. Saxton, P. Lavertu, L. A. Rybicki, R. M. Esclamado, B. G. Wood, M. Strome, and M. A. Carroll Maximizing Local Control and Organ Preservation in Stage IV Squamous Cell Head and Neck Cancer With Hyperfractionated Radiation and Concurrent Chemotherapy J. Clin. Oncol., March 1, 2002; 20(5): 1405 - 1410. [Abstract] [Full Text] [PDF]

				C. M. George, N. J. Vogelzang, B. I. Rini, F. J. Geoffroy, P. Kollipara, and W. M. Stadler A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma Ann. Onc., January 19, 2002; 13(1): 116 - 120. [Abstract] [Full Text] [PDF]

				M. E. Poole, S. L. Sailer, J. G. Rosenman, J. E. Tepper, M. C. Weissler, W. W. Shockley, W. G. Yarbrough, H. C. Pillsbury III, M. J. Schell, and S. A. Bernard Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck for Organ Preservation and Palliation Arch Otolaryngol Head Neck Surg, December 1, 2001; 127(12): 1446 - 1450. [Abstract] [Full Text] [PDF]

				F. R. Khuri, J. R. Rigas, R. A. Figlin, R. J. Gralla, D. M. Shin, R. Munden, N. Fox, M. R. Huyghe, Y. Kean, S. D. Reich, et al. Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., May 15, 2001; 19(10): 2626 - 2637. [Abstract] [Full Text] [PDF]

				A. A. Forastiere, T. Leong, E. Rowinsky, B. A. Murphy, D. R. Vlock, R. C. DeConti, and G. L. Adams Phase III Comparison of High-Dose Paclitaxel + Cisplatin + Granulocyte Colony-Stimulating Factor Versus Low-Dose Paclitaxel + Cisplatin in Advanced Head and Neck Cancer: Eastern Cooperative Oncology Group Study E1393 J. Clin. Oncol., February 15, 2001; 19(4): 1088 - 1095. [Abstract] [Full Text] [PDF]

				J. Nemunaitis, F. Khuri, I. Ganly, J. Arseneau, M. Posner, E. Vokes, J. Kuhn, T. McCarty, S. Landers, A. Blackburn, et al. Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer J. Clin. Oncol., January 15, 2001; 19(2): 289 - 298. [Abstract] [Full Text] [PDF]

				C. Heise, M. Lemmon, and D. Kirn Efficacy with a Replication-selective Adenovirus Plus Cisplatin-based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration Clin. Cancer Res., December 1, 2000; 6(12): 4908 - 4914. [Abstract] [Full Text]

				K. J. Harrington, G. Rowlinson-Busza, K. N. Syrigos, R. G. Vile, P. S. Uster, A. M. Peters, and J. S. W. Stewart Pegylated Liposome-encapsulated Doxorubicin and Cisplatin Enhance the Effect of Radiotherapy in a Tumor Xenograft Model Clin. Cancer Res., December 1, 2000; 6(12): 4939 - 4949. [Abstract] [Full Text]

				J. Nemunaitis, I. Ganly, F. Khuri, J. Arseneau, J. Kuhn, T. McCarty, S. Landers, P. Maples, L. Romel, B. Randlev, et al. Selective Replication and Oncolysis in p53 Mutant Tumors with ONYX-015, an E1B-55kD Gene-deleted Adenovirus, in Patients with Advanced Head and Neck Cancer: A Phase II Trial Cancer Res., November 1, 2000; 60(22): 6359 - 6366. [Abstract] [Full Text]

				W. C. To, B. G. Wood, J. C. Krauss, M. Strome, R. M. Esclamado, P. Lavertu, D. Dasko, J. A. Kim, G. E. Plautz, B. E. Leff, et al. Systemic Adoptive T-Cell Immunotherapy in Recurrent and Metastatic Carcinoma of the Head and Neck: A Phase 1 Study Arch Otolaryngol Head Neck Surg, October 1, 2000; 126(10): 1225 - 1231. [Abstract] [Full Text] [PDF]

				U. Schaefer, O. Micke, P. Schueller, and N. Willich Recurrent Head and Neck Cancer: Retreatment of Previously Irradiated Areas with Combined Chemotherapy and Radiation Therapy-Results of a Prospective Study Radiology, August 1, 2000; 216(2): 371 - 376. [Abstract] [Full Text]

				R. Bryce, S. Hettiaratchy, J. Clarke, J. Täubel, C. Besa, and R. Smith Burns after photodynamic therapy BMJ, June 24, 2000; 320(7251): 1731 - 1731. [Full Text]

				I. Ganly, D. Kirn, S. G. Eckhardt, G. I. Rodriguez, D. S. Soutar, R. Otto, A. G. Robertson, O. Park, M. L. Gulley, C. Heise, et al. A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer Clin. Cancer Res., March 1, 2000; 6(3): 798 - 806. [Abstract] [Full Text]

				H. Shiga, E. I. Heath, A. A. Rasmussen, B. Trock, P. G. Johnston, A. A. Forastiere, M. Langmacher, A. Baylor, M. Lee, and K. J. Cullen Prognostic Value of p53, Glutathione S-Transferase {{pi}}, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer Clin. Cancer Res., December 1, 1999; 5(12): 4097 - 4104. [Abstract] [Full Text] [PDF]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				A. S. Garden, B. S. Glisson, K. K. Ang, W. H. Morrison, S. M. Lippman, R. M. Byers, F. Geara, G. L. Clayman, D. M. Shin, D. L. Callender, et al. Phase I/II Trial of Radiation With Chemotherapy ""Boost"" for Advanced Squamous Cell Carcinomas of the Head and Neck: Toxicities and Responses J. Clin. Oncol., August 1, 1999; 17(8): 2390 - 2390. [Abstract] [Full Text] [PDF]

				E. E. Vokes, R. R. Weichselbaum, S. M. Lippman, and W. K. Hong Head and Neck Cancer N. Engl. J. Med., January 21, 1993; 328(3): 184 - 194. [Full Text]